论文部分内容阅读
[目的]探讨替吉奥联合奥沙利铂(SOX)方案联合细胞因子诱导的杀伤细胞(CIK)治疗老年转移性胃癌的近期疗效。[方法]采用信封法将143例老年转移性胃癌患者随机分为SOX组(SOX方案化疗)72例和CIK组(SOX方案化疗+CIK治疗)71例,对比分析两组患者的近期疗效差异。[结果]SOX组的缓解率(34.7%)显著低于CIK组(52.1%),差异具有统计学意义(P<0.05),CIK组的总有效率(88.7%)高于SOX组(80.6%),但差异无统计学意义(P>0.05);治疗后CIK组的CD3+、CD4+、CD4+/CD8+水平显著高于SOX组(P<0.05),CD8+水平低于SOX组(P<0.05);治疗后CIK组的Karnofasky评分显著高于SOX组(P<0.05);SOX组和CIK组的血小板减少、红细胞减少、腹泻、恶心呕吐、口腔黏膜炎、肝功能损害、周围神经反应、手足综合征发生率差异均不具有统计学意义(P>0.05),CIK组的白细胞减少发生率(26.8%)显著低于SOX组(44.4%,P<0.05)。[结论]SOX方案联合CIK治疗老年转移性胃癌患者具有提高治疗效果的作用,且能增强患者的免疫能力。
[Objective] To explore the short-term curative effect of tegaserod combined with oxaliplatin (SOX) and cytokine-induced killer (CIK) in the treatment of elderly patients with metastatic gastric cancer. [Methods] A total of 143 elderly patients with metastatic gastric cancer were enrolled in the envelope method. They were randomly divided into SOX group (SOX chemotherapy) group (n = 72) and CIK group (SOX chemotherapy + CIK group) [Results] The response rate of SOX group (34.7%) was significantly lower than that of CIK group (52.1%), the difference was statistically significant (P <0.05). The total effective rate of CIK group (88.7% (P <0.05). The levels of CD3 +, CD4 + and CD4 + / CD8 + in CIK group were significantly higher than those in SOX group and CD8 + group (P <0.05), but not in SOX group. The Karnofasky score of CIK group was significantly higher than that of SOX group (P <0.05) after treatment. Thrombocytopenia, erythrocyte reduction, diarrhea, nausea and vomiting, oral mucositis, liver damage, peripheral nerve reaction, hand-foot syndrome (P> 0.05). The incidence of leukopenia in CIK group (26.8%) was significantly lower than that in SOX group (44.4%, P <0.05). [Conclusion] SOX regimen combined with CIK in the treatment of elderly patients with metastatic gastric cancer has the effect of improving the therapeutic effect and can enhance the immunocompetence of patients.